Mereo BioPharma

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Mereo BioPharma sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 7 completed early-phase tilt top decile by trial count

Mereo BioPharma: 10 sponsored US clinical trials, none currently recruiting.

Mereo BioPharma sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pulmonary Disease, Chronic Obstructive, with 1 trials.

Top-decile sponsor footprint

Mereo BioPharma ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 14/100

7 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (70.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED Phase 1

A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors

NCT04761198
COMPLETED Phase 2

A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.

NCT03636347
COMPLETED Phase 1

The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants

NCT03498170
COMPLETED Phase 2

A 6 Month Safety Extension Study of MBGS205

NCT02908074
COMPLETED Phase 2

Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease

NCT02700919
COMPLETED Phase 2

Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism

NCT02730169
TERMINATED Phase 2

Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery

NCT01336959
TERMINATED Phase 2

Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men

NCT01200862
COMPLETED Phase 2

BGS649 Monotherapy in Moderate to Severe Endometriosis Patients

NCT01190475
TERMINATED Phase 2

A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

NCT01116440

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 8

Therapeutic Areas

Pulmonary Disease, Chronic Obstructive 1
Interaction 1
Endometriosis 1

How the Mereo BioPharma early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open); 7 completed (70%).

Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Pulmonary Disease, Chronic Obstructive (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Mereo BioPharma: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Mereo BioPharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Mereo BioPharmaAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Mereo BioPharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Mereo BioPharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Mereo BioPharma page

10 registered trials is a research-attention snapshot, not an endorsement of Mereo BioPharma or any single study.

  • None of Mereo BioPharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Pulmonary Disease, Chronic Obstructive is the condition Mereo BioPharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pulmonary Disease, Chronic Obstructive trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Mereo BioPharma pipeline card: 10 registered trials from official public datasets.Report a data error.